title: Hypogonadism in beta-thalassemic adolescents: a characteristic pituitary-gonadal impairment. The ineffectiveness of long-term iron chelation therapy.
abstract: The pituitary-gonadal function was studied in 18 beta-thalassemic female adolescents, 8 with delayed puberty and 10 with primary amenorrhea,treated with repeated transfusions and long-term iron chelation therapy by subcutaneous infusion. A 100 micrograms gonadotropin-releasing hormone (GnRH) test, a double-bolus GnRH test after estradiol administration in non-responders, a 400 micrograms thyrotropin-releasing hormone (TRH) test and a 'high dose' human menopausal gonadotropin (hMG) test were performed. LH and FSH peak levels were significantly lower in thalassemic patients than in controls, both in the 100 micrograms GnRH test (LH was 4.3 +/- 0.7 mIU/ml vs 40.8 +/- 6.0 mIU/ml and FSH 3.3 +/- 0.5 mIU/ml vs 9.6 +/- 1.1 mIU/ml, respectively) and in the double-bolus GnRH test (LH was 2.3 +/- 0.2 mIU/ml vs 59.0 +/- 4.9 mIU/ml and FSH 1.8 +/- 0.3 mIU/ml vs 14.0 +/- 1.0 mIU/ml). The mean prolactin response to the TRH test was 27.8 +/- 3.2 ng/ml. After the 'high dose' hMG test 12 out of 14 admitted patients showed a poor response, lower than 250 pg/ml. Our data suggest that the hypogonadotropic condition of the thalassemic adolescents is due to pituitary hyporesponsiveness to GnRH and that most of these patients also have an impairment of ovarian function. Both conditions are a consequence of iron deposits in glands. Moreover, there is evidence that pituitary-gonadal function cannot be preserved by long-term iron chelation therapy.
authors: II Department of Obstetrics and Gynecology, Ospedale Civico, Sicily, Italy.
authors: A
authors: A
authors: Allegra
authors: M
authors: M
authors: Capra
authors: L
authors: L
authors: Cuccia
authors: M L
authors: ML
authors: Pulejo
authors: L
authors: L
authors: Raineri
authors: F
authors: F
authors: Corselli
authors: M C
authors: MC
authors: Traina
authors: C
authors: C
authors: Giannola
authors: A
authors: A
authors: La Grutta
mesh_terms: D000293:Adolescent; D015913:Chelation Therapy; D002648:Child; D003676:Deferoxamine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D006801:Humans; D007006:Hypogonadism / Q000209:etiology*; D007501:Iron; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000494:pharmacology; D010053:Ovary / Q000378:metabolism; D010902:Pituitary Gland / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D013789:Thalassemia / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
chemical_list: D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D008596:Menotropins; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D007501:Iron; D003676:Deferoxamine